---
title: "Aligos Therapeutics receives USD 25 million upfront in Greater China pevifoscorvir license deal with Amoytop"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291839191.md"
description: "Aligos Therapeutics received a $25 million upfront payment from Amoytop for an exclusive Greater China license of pevifoscorvir sodium. The deal includes up to $420 million in potential milestones and tiered royalties. Aligos retains global rights outside Greater China. The NMPA CDE granted Breakthrough Therapy Designation, enabling priority review."
datetime: "2026-07-06T20:05:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291839191.md)
  - [en](https://longbridge.com/en/news/291839191.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291839191.md)
---

# Aligos Therapeutics receives USD 25 million upfront in Greater China pevifoscorvir license deal with Amoytop

-   Aligos received an upfront payment of USD 25 million from an exclusive Greater China license for pevifoscorvir sodium with Amoytop. \* Deal includes up to USD 420 million in clinical, regulatory, sales milestones; tiered high single-digit royalties on net sales. \* Aligos keeps development and commercialization rights outside Greater China, including the U.S. and Europe. \* China’s NMPA CDE granted Breakthrough Therapy Designation for pevifoscorvir sodium, enabling priority NDA review. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aligos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607061605PRIMZONEFULLFEED9757506) on July 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ALGS.US](https://longbridge.com/en/quote/ALGS.US.md)
- [688278.CN](https://longbridge.com/en/quote/688278.CN.md)

## Related News & Research

- [Aligos Q2 FY26 net loss narrows 91% to $1.5 million](https://longbridge.com/en/news/295103944.md)
- [Aligos completes enrollment in Phase 2 B-SUPREME trial for chronic hepatitis B drug pevifoscorvir sodium](https://longbridge.com/en/news/292485727.md)
- [3 genius artificial intelligence (AI) stocks to buy right now](https://longbridge.com/en/news/294816326.md)
- [RARE: Record Q2 revenue and upcoming gene therapy launches position the company for 2027 profitability](https://longbridge.com/en/news/294883644.md)
- [Iovance publishes corporate presentation highlighting Amtagvi TIL therapy rollout and pipeline expansion in solid tumors](https://longbridge.com/en/news/295105932.md)